SPOTLIGHT -
Dr. Micallef on NuQ Blood Tests in Prostate Cancer
Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Read More
Biomarker Assay as Alternative to Early-Stage Prostate Cancer Detection
Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses a study that examined the efficacy of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
